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CD44 is an integral membrane glycoprotein which plays an
important role in cell–substrate and cell–cell interactions including
lymphocyte homing; lymphocyte, endothelial and mucosal interac-
tions; cytokine release, T-cell activation; homotypic and heterotypic
cell–cell adhesion and cytoskeletal interactions with the extra-
cellular matrix (Lesley et al, 1993). Altered expression of CD44
has been observed in a large number of tumours of adult life
(Matsumura and Tarin, 1992; Abbasu et al, 1993; Heider et al,
1993a; 1993b; Joensuu et al, 1993; Tanabe et al, 1993; Matsumura
et al, 1994; Penno et al, 1994; Southgate et al, 1995; Harwood et al,
1996; Nagabhushan et al, 1996) and in the paediatric malignancy
neuroblastoma (Favrot et al, 1993; Gross et al, 1994, 1995;
Shtivelmann and Bishop, 1991). The aim of this study was to docu-
ment the pattern of expression of CD44 by rhabdomyosarcomas and
to determine the relationship of CD44 expression to prognosis.
MATERIALS AND METHODS
Tumour samples collected prospectively at the time of diagnostic
biopsy or definitive tumour excision in Leeds were used for this
study. Tumour samples from 28 patients (age range 22 months to
15 years) diagnosed as having rhabdomyosarcoma between 1977
and 1994 were studied. Eleven patients were male and 17 female.
Seventeen patients are alive in first remission, two are alive in
second or subsequent remission, seven children are dead of disease
and two children have died from treatment related complications.
Distribution by site, stage and histological type are summarized in
Table 1. Tumours had been characterized using an antibody panel
including desmin, vimentin and MyoD1.
Immunohistochemical analysis of CD44 was carried out using a
standard streptavidin–biotin–horseradish peroxidase immunohisto-
chemistry protocol [Streptavidin/ABC/HRP detection kit (DAKO)].
Previously characterized primary antibodies recognizing core
epitope one (BRIC 222 at 1/60), epitope two (BRIC235 at 1/40) and
epitope three (KZ-1 at 1/40) were obtained from International Blood
Group Reference Laboratory, Bristol (Anstee et al, 1991). The
secondary antibody was a biotinylated F(ab´)2 rabbit anti-mouse
immunoglobulin (DAKO, Buckinghamshire, UK). Labelling was
detected using diaminobenzidine chromagen and sections counter-
stained with haematoxylin. Fresh-frozen and paraffin sections were
labelled in a similar fashion although formalin-fixed tissue was
pretreated by dewaxing and microwave antigen retrieval (Gown et al,
1993). Control samples throughout included omission of primary
antibody and the presence of non-tumour tissue within each section
examined. Slides were assessed blind by an experienced tumour
pathologist (KM) and labelling scored. Tumours were considered
negative when tumour cell labelling was less than 40%, indetermi-
nate when 40–60% of tumour cells labelled and positive when
greater than 60% of tumour cells labelled.
Fisher’s exact test with one-tail analysis of CD44 expression by
histological subtype was undertaken. For analysis of disease
progression the log-rank test was used for testing the difference
between the groups. The level of confidence was set at P = 0.05.
Statistical analysis was undertaken using SPSS for Windows
(version 6.1) (Chicago, IL, USA).
RESULTS
Identical labelling patterns were seen when matched pairs of fresh-
frozen and formalin-fixed paraffin-embedded tumour samples were
analysed. There was good correlation in the expression patterns
obtained with labelling using BRIC222 and 235. The antibody
KZ-1 labelled more cells in each sample than BRIC222 and 235.
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One tumour had approximately equal numbers of labelled and
unlabelled cells and has therefore not been included in statistical
analysis by predominant cell phenotype. Eleven of 20 favourable
histology tumours expressed CD44 (Figure 1) compared with one of
seven unfavourable histology tumours (Figure 2) P = 0.07 (Table 2).
Eleven of 12 patients with CD44 positive tumours are disease-free
in first remission compared with five of 15 patients with CD44-
negative tumours P < 0.001 (Table 3). The Kaplan–Meier survival
curve is shown in Figure 3. Nineteen of 27 patients are alive more
than 3 years from diagnosis. Seven of the remaining patients died
from disease within 3 years of diagnosis and one patient died
disease-free from treatment-related toxicity.
DISCUSSION
CD44 is a transmembrane glycoprotein expressed on virtually all
cell types where it acts as a receptor for hyaluronate (Picker et al,
1989; Culty et al, 1990; Lesley et al, 1993). It is encoded by a gene
occupying 60–80 kb located at chromosome 11p13 and consists of
at least 21 exons (Forsberg et al, 1989; Jackson et al, 1992;
Screaton et al, 1992). The CD44 molecule has three core epitopes
encoded by ten exons with alternative mRNA splicing of the
remaining exons generating multiple isoforms (CD44v). The stan-
dard form of CD44 (CD44s) is expressed on almost all cell types
and is heavily glycosylated. Variant isoforms are expressed in a
cell- and tissue-specific manner (Arch et al, 1992; Herrlich et al,
1993; Lesley et al, 1993; Mackay et al, 1994).
Table 1 Numbers of patients by site and stage of tumour
I II III IV Total
FU FU FU FU
Orbit 1 1
PMHN 11
non-PMHN 1 1 2 1 1 6
GU–BP 61 7
GU–non-BP 1 1 2
Extremity 1 1 4 6
Other 22 1 5
Total 2 1 1 1 14 4 3 2 28
F = botryoid, embryonal, mixed embryonal undifferentiated and spindle cell tumours; U = alveolar and undifferentiated tumours. Stage I, II, III and IV refer to IRS
clinical groups. PMHN = tumours involving parameningeal sites; non-PMHN = tumours of head and neck not involving parameningeal areas or orbit; GU–BP =
tumours arising in bladder or prostate; GU–non-BP = tumours arising in genitourinary tract other than bladder or prostate; Extremity = tumour arising in a limb;
Other = tumours arising in all other sites.
Table 2 Table for testing probability of CD44 expression correlating with
histological subtype
CD44-positive CD44-negative Total
Favourable 11 9 20
Unfavourable 1 6 7
Total 12 15 27
Favourable = tumours of botryoid, embryonal or spindle cell type;
unfavourable = alveolar and undifferentiated. P = 0.07.
Table 3 Table for testing probability of association of CD44 expression with
disease progression
CD44-positive CD44-negative Total
Disease-free in 1st remission 11 5 16
Disease progression 1 10 11
Total 12 15 27
P = 0.001.
Figure 1 Rhabdomyosarcoma with focal labelling of the majority of tumour
cells for CD44, x120
Figure 2 Labelling of inflammatory cells for CD44 within an alveolar RMS
negative for CD44, x120920 G Humphrey et al
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Qualitative and quantitative changes in expression of CD44
have been demonstrated in vitro in the vascular dissemination of
melanoma (Birch et al, 1991) and lymphoma cells (Sy et al, 1991),
and in the migration of rat pancreas carcinoma cells on the extra-
cellular matrix (Günthert et al, 1991). In vivo, enhanced or up-
regulation of CD44 (core or variant) expression has been found to
be related to tumour progression in breast (Joensuu et al, 1993),
colorectal (Abbasu et al, 1993a; Tanabe et al, 1993; Wielenga et al,
1993), gastric (Heider et al, 1993a; Mayer et al, 1993), cervical
(Dall et al, 1994) and bladder (Matsumura et al, 1994; Southgate et
al, 1995) carcinomas, non-Hodgkin’s lymphoma (Koopman et al,
1993) and brain tumours (Terpe et al, 1993). Conversely, loss of or
reduction in expression of CD44v isoforms is associated with
disease progression in squamous cell (Salmi et al, 1993) and
endometrial carcinomas (Fujita et al, 1994). In addition, loss of
CD44s isoforms has been reported in metastatic prostatic
(Nagabhushan et al, 1996) and bladder cancer (Southgate et al,
1995) and melanomas during their vertical growth phase
(Harwood et al, 1996).
Several studies have confirmed the potential importance of
CD44 as a prognostic indicator for neuroblastoma tumours with
stage 1–3 and 4s disease expressing CD44 (Favrot et al, 1993;
Gross et al, 1994, 1995; Christiansen et al, 1995; Terpe et al, 1995).
Studies of stage 4 neuroblastomas comparing MYCN amplification
with CD44 expression have shown that there is a highly significant
inverse relationship between MYCN amplification and CD44
expression (Favrot et al, 1993; Gross et al, 1994, 1995; Christiansen
et al, 1995; Terpe et al, 1995). In rhabdomyosarcoma, MYCN
amplification appears to be a relatively infrequent observation
except in those of alveolar subtype (Dias et al, 1990; Mailet et al,
1992; Driman et al, 1994; Tsuda et al, 1998). This study combined
with that of Saxon et al (1997) suggests that most alveolar rhab-
domyosarcomas are CD44-negative; therefore, studies correlating
CD44 expression with MYCN amplification should be carried out
on embryonal and alveolar rhabdomyosarcomas to see if MYCN
amplification is directly related to histological type and to establish
if the two are causally related.
In 1958, Horn and Enterline divided rhabdomyoscarcomas into
four subtypes – embryonal, botryoid, alveolar and pleiomorphic.
In an attempt to improve the prognostic value of basic histology an
alternative classification divides tumours into: favourable
(botryoid and spindle cell), moderately favourable (all other
embryonal tumours), and unfavourable (solid alveolar, alveolar
and undifferentiated) (Newton et al, 1995). In 1997, Saxon
reported that none of five alveolar rhabdomyosarcomas studied
expressed CD44 and that embryonal tumours had a heterogenous
pattern of labelling but did not attempt to correlate this with
disease outcome. This study suggests that alveolar tumours are
predominantly CD44-negative. This small study appears to indi-
cate that low expression of CD44 correlates with poor outcome,
these results must be interpreted with caution because of the small
sample size and possible confounding influence of subset analysis.
To confirm the hypothesis that low CD44 expression predicts poor
outcome and to establish if this is independent of histological
subtype further studies should be performed using a large retro-
spective data set with multivariate analysis.
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